Tuberculosis Screening in Paraguayan Prisons (Prinose)
Primary Purpose
Volatile Organic Compounds, Radiography
Status
Recruiting
Phase
Not Applicable
Locations
Paraguay
Study Type
Interventional
Intervention
electronic nose device
dig chest Xray with automated readings
Sponsored by
About this trial
This is an interventional diagnostic trial for Volatile Organic Compounds focused on measuring tuberculosis, vulnerable populations, screening algorithms, cost effectiveness, neural networks, artificial intelligence
Eligibility Criteria
Inclusion Criteria:
- All persons, either being a prisoner or employee, of the involved penal institutions after providing informed consent, including those with known active TB disease and/or currently on TB treatment
Exclusion Criteria:
A potential participant who meets any of the following criteria will be excluded from participation in this study:
- Unable to exhale breath through the AeoNose™ during five minutes due to respiratory insufficiency
- Unable to stand in an upright position for the CXR
- Unable to communicate and comply with the instructions of the study team
Sites / Locations
- Buen PastorRecruiting
- UPI
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
AeoNose
Arm Description
the AeoNose will be compared with digital ChestXray and the conventional methods of establishing TB diagnosis
Outcomes
Primary Outcome Measures
Volatile organic compound signal as measured with the AeoNose™
The exhaled breath 'smell print' of each participant will be compared over time at baseline, 3 months and 6 months with sputum microbiology results and digital Chest Xray to establish sensitivity and specificity of electronic nose signal to diagnose Tuberculosis
Tuberculosis probablity score using Computed Automated detection software CAD4TB® on chest Xrays
Ranges from 0 to 100, where 0 would mean the lowest probability of having Tuberculosis and 100 would be the highest probability of having Tuberculosis.
Positive mycobacterial sputum test
positive GenXpert test and/or mycobacterial cultures are used to establish Tuberculosis diagnosis
Secondary Outcome Measures
Comparison of predictive value of volatile organic compound signal with Tuberculosis Probability Score
comparison of correct positive predictions for active TB, with AeoNose (positive/ negative test result) and Cad4TB software from chest Xrays providing probability scores from 0-100 points
added value of the use of AeoNose and Cad4TB as a TB screening algorithm in vulnerable populations
evaluation of the combined use of both AeoNose and Cad4TB probability score to predict active TB
Full Information
NCT ID
NCT04407325
First Posted
April 23, 2020
Last Updated
March 30, 2023
Sponsor
Radboud University Medical Center
Collaborators
European Union, Instituto de Saude Publica da Universidade do Porto, VHIR, University Medical Center Groningen, Laboratorio central de salud publica, Paraguay, Instituto Nacional de Enfermedades Respiratorias y del Ambiente Juan Max Boetner, National TB program Paraguay, IICS Paraguay
1. Study Identification
Unique Protocol Identification Number
NCT04407325
Brief Title
Tuberculosis Screening in Paraguayan Prisons
Acronym
Prinose
Official Title
Tuberculosis Screening With AeoNose and CAD4TB in Paraguayan Prisons
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 18, 2021 (Actual)
Primary Completion Date
July 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center
Collaborators
European Union, Instituto de Saude Publica da Universidade do Porto, VHIR, University Medical Center Groningen, Laboratorio central de salud publica, Paraguay, Instituto Nacional de Enfermedades Respiratorias y del Ambiente Juan Max Boetner, National TB program Paraguay, IICS Paraguay
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Two diagnostic tools for TB screening in high risk groups need additional assessment: the AeoNose™, an 'electronic nose device' for breath sampling, and digital chest X-ray (CXR) with computer aided detection with CAD4TB® software. This study will systematically screen prisoners and its' employees for TB, test the diagnostic performance of AeoNose™ and CAD4TB (both individually and together) as a TB screening tool and and establish Mycobacterium tuberculosis epidemiology in Paraguayan prisons.
Detailed Description
The aim of the World Health Organization (WHO) "End TB Strategy" is to end the global pandemic by 2035. To be able to succeed, better point-of-care (POC) tests are urgently needed to improve screening of high-risk populations. Prisons are recognized worldwide as high risk environments for the concentration, amplification and transmission of TB among prisoners and their communities outside. Paraguayan penal institutions are known to have very high incidence rates of active TB (3000-5000/100.000, according to Paraguayan Ministry of Justice). Two diagnostic tools for TB screening in high risk groups will be evaluated: the AeoNose™, an 'electronic nose device' for breath sampling, and digital chest X-ray (CXR) with computer aided detection with CAD4TB® software. This study will systematically screen prisoners and its' employees for TB, test the diagnostic performance of AeoNose™ and CAD4TB® and assess prison Mycobacterium tuberculosis epidemiology through several objectives: Objective: 1. Assessment of the sensitivity and specificity of the AeoNose™ and its utility for mass TB screening in high incidence settings. 2. Evaluation of the feasibility and utility of CAD4TB® digital CXR as a mass screening tool for TB. 3. Identification of factors that affect diagnostic accuracy of AeoNose™ and CAD4TB®. 4. Assessment of TB epidemiology in Paraguayan prisons and identification of mycobacterial strains.
Study design: Diagnostic cohort study. Study population: Detainees (PPL) of Paraguayan penal institutions as well as their employees. Nature and extent of the burden and risks associated with participation, benefit and group relatedness.
Individual burden: all participants will perform one visit with a medical doctor for medical history, physical exam, digital X-ray (with CAD4TB®) and AeoNose sampling. Participants will be offered voluntary HIV testing and counseling. In case of presumptive TB (estimated 20-30% of participants) two sputum samples will be taken, either spontaneous or saline-induced. One sample is tested with GeneXpert and the other with liquid mycobacterial culture. Cases of presumptive TB with both negative GeneXpert® and culture results will be followed-up after three and six months for repeat testing.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Volatile Organic Compounds, Radiography
Keywords
tuberculosis, vulnerable populations, screening algorithms, cost effectiveness, neural networks, artificial intelligence
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
outcomes of individual smell prints and digital ChestXrays will be compared with sputum sampling for GenXpert and Mycobacterial culture
Masking
None (Open Label)
Allocation
N/A
Enrollment
5000 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
AeoNose
Arm Type
Experimental
Arm Description
the AeoNose will be compared with digital ChestXray and the conventional methods of establishing TB diagnosis
Intervention Type
Device
Intervention Name(s)
electronic nose device
Other Intervention Name(s)
(AeoNose, The eNose Company, the Netherlands)
Intervention Description
electronic nose device will be tested as a triage instrument for tuberculosis in a high risk population
Intervention Type
Device
Intervention Name(s)
dig chest Xray with automated readings
Other Intervention Name(s)
CAD4TB computed automated detection software
Intervention Description
software for tuberculosis detection on digital Chest Xray providing a probability score from 0-100
Primary Outcome Measure Information:
Title
Volatile organic compound signal as measured with the AeoNose™
Description
The exhaled breath 'smell print' of each participant will be compared over time at baseline, 3 months and 6 months with sputum microbiology results and digital Chest Xray to establish sensitivity and specificity of electronic nose signal to diagnose Tuberculosis
Time Frame
Baseline/ change from baseline at 3 and 6 months
Title
Tuberculosis probablity score using Computed Automated detection software CAD4TB® on chest Xrays
Description
Ranges from 0 to 100, where 0 would mean the lowest probability of having Tuberculosis and 100 would be the highest probability of having Tuberculosis.
Time Frame
Baseline/ change from baseline at 3 and 6 months
Title
Positive mycobacterial sputum test
Description
positive GenXpert test and/or mycobacterial cultures are used to establish Tuberculosis diagnosis
Time Frame
Baseline/ change from baseline at 3 and 6 months
Secondary Outcome Measure Information:
Title
Comparison of predictive value of volatile organic compound signal with Tuberculosis Probability Score
Description
comparison of correct positive predictions for active TB, with AeoNose (positive/ negative test result) and Cad4TB software from chest Xrays providing probability scores from 0-100 points
Time Frame
Baseline/ change from baseline at 3 and 6 months
Title
added value of the use of AeoNose and Cad4TB as a TB screening algorithm in vulnerable populations
Description
evaluation of the combined use of both AeoNose and Cad4TB probability score to predict active TB
Time Frame
Baseline/ change from baseline at 3 and 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
All persons, either being a prisoner or employee, of the involved penal institutions after providing informed consent, including those with known active TB disease and/or currently on TB treatment
Exclusion Criteria:
A potential participant who meets any of the following criteria will be excluded from participation in this study:
Unable to exhale breath through the AeoNose™ during five minutes due to respiratory insufficiency
Unable to stand in an upright position for the CXR
Unable to communicate and comply with the instructions of the study team
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Luis Gomez Pacielo, MD
Phone
+595961889657
Email
luis.gomez@RadboudUMC.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cecile Magis-Escurra, MD,PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Buen Pastor
City
Asuncion
State/Province
Central
Country
Paraguay
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claudia Pinanez, MD
Email
claupinanez@hotmail.com
Facility Name
UPI
City
Asuncion
State/Province
Central
Country
Paraguay
Individual Site Status
Completed
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
https://www.eusattb.net/
Description
EUSAT-RCS TB research consortium
Learn more about this trial
Tuberculosis Screening in Paraguayan Prisons
We'll reach out to this number within 24 hrs